Onglyza belongs to a class of drugs known as incretin mimetics, which stimulate the production of insulin in the pancreas to help regulate blood sugar levels in patients with type-2 diabetes.
Incretin mimetics are a relatively new family of diabetes drugs which gained popularity after Avandia, another popular diabetes medication, was recalled after it was linked to a dramatic increase in the risk of cardiac death.
Pharmaceutical companies and physicians are on the lookout for safer alternatives for the treatment of type-2 diabetes, and incretin mimetics held promise. However, following the Avandia recall, experts are on high alert about potential heart risks and other dangerous side effects associated with the diabetes drugs.
Onglyza Heart Failure Risk
Bristol-Myers Squibb and AstraZeneca recently funded a study that found that patients who used Onglyza had a higher rate of hospitalizations related to heart failure.
The SAVOR study was published in the New England Journal of Medicine in 2013. Researchers evaluated 16,492 patients who were diagnosed with type-2 diabetes, with the goal of helping doctors determine which diabetes medications were right for their patients. Patients who took Onglyza were slightly more likely to be hospitalized for heart failure than patients who took other diabetes medications.
Heart failure is a medical condition in which the heart muscle is too weak to pump enough blood throughout the body. Certain conditions such as high blood pressure or coronary artery disease may gradually weaken the heart and lead to heart failure.
Patients who suffer heart failure typically must make significant lifestyle changes such as improving their diet, reducing salt intake, exercising, losing weight and managing stress.
Although the increase in hospitalizations for Onglyza heart failure was not statistically significant, it has raised concern for experts who believe the potential link deserves further investigation.
In April 2015, an advisory committee to the U.S. Food and Drug Administration urged the agency to require AstraZeneca and Bristol-Myers Squibb to include information about the risk of Onglyza heart failure on the drug’s label.
Onglyza Pancreatitis/Pancreatic Cancer Risk
In March 2013, the FDA announced it would investigate reports of a possible increased risk of pancreatitis and pancreatic cancer from incretin mimetic drugs like Onglyza.
The announcement followed a study published in the March 2013 journal of Diabetes, in which researchers found a strong link between diabetes medications like Onglyza and pancreatic cancer.
In the study, researchers analyzed autopsies performed on 20 people who had diabetes, including eight who used an incretin mimetic drug such as Onglyza.
The results showed that patients who had taken an incretin mimetic had a pancreas that was 40 percent larger than normal. These patients also showed a six-fold increase in the number of beta cells in their pancreases as well as “eccentric” pre-cancerous cell growth and small tumors called adenomas, which can become malignant and cause pancreatic cancer.
Just a month prior, in February 2013, researchers at Johns Hopkins found that diabetics hospitalized with pancreatitis were twice as likely to be taking an incretin mimetic drug to treat diabetes such Onglyza, Januvia, Byetta or Victoza.
Onglyza Thyroid Cancer Risk
The FDA has been investigating a link between incretin mimetics such as Onglyza and a heightened risk for thyroid cancer since 2009.
In 2011, the agency published a safety communication after studies showed a higher rate of malignant thyroid tumors in rodents treated with Victoza, an incretin mimetic like Onglyza.
Another study conducted by researchers at the University of California, Los Angeles (UCLA) and published in Gastroenterology revealed that people who used the incretin mimetic drug Byetta were almost five times more likely to develop thyroid cancer than those who took the diabetes medication Avandia (rosiglitazone).
In general, Onglyza lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual Onglyza lawsuit or Ongylyza class action lawsuit is best for you. Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2015 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Onglyza Lawsuit Investigation
If you or a loved one were injured from Onglyza side effects such as heart failure, thyroid cancer or pancreatic cancer, you may have a legal claim. See if you qualify to pursue compensation and join a free Onglyza lawsuit investigation by submitting your information for a free case evaluation.
An attorney will contact you if you qualify to discuss the details of your potential case.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- What year did you/your loved one start taking Onglyza?*
- Which of the following problems did you/your loved one experience after taking Onglyza?*
-
Heart Failure
-
Heart Attack
-
Pancreatic Cancer
-
Thyroid Cancer
-
Death
-
Other (please describe in the additional details box below)
-
- What year were you/your loved one diagnosed with one or more of these problems?*
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.*
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 141) {gformInitChosenFields(‘#input_141_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_141_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_141_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [141, 1]) } );
The post Onglyza Won’t Prevent Heart Attack, Study Suggests appeared first on Top Class Actions.
No comments:
Post a Comment